Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SN38 is the active metabolite of the widely used cancer drug irinotecan, marketed as Camptosar in the US.
Subscribe to our email newsletter
Enzon has initiated the phase-II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers in US to patients diagnosed with metastatic colon cancer.
PEG-SN38 is being developed using Enzon’ proprietary PEGylation technology. SN38 is the active metabolite of the widely used cancer drug irinotecan (also CPT-11), marketed as Camptosar in the US.
Two phase-I studies were conducted evaluating different dosing schedules of PEG-SN38. No cumulative toxicity has been reported. A recommended phase-II dose was established in April 2009.
Jeffrey Buchalter, Chairman and CEO, Enzon, said: “We are pleased to have the first PEG-SN38 Phase II trial open in early summer as promised. We are encouraged by the safety profile in the Phase I trials and are looking forward to this next phase of development.